EXCLUSIVE: Longeveron's Lomecel-B Data In Alzheimer's Disease Published In Medical Journal

Longeveron Inc LGVN announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal.

The 33-subject trial met its primary endpoint, demonstrating that Lomecel-B was well tolerated. 

Data supported further exploration of Lomecel-B, particularly the therapeutic potential to slow cognitive decline and improve quality of life in patients with AD. 

Read Next: Exclusive: Longeveron Kickstarts Its Mid-Stage Alzheimer's Disease Trial.

What Happened: Patients receiving Lomecel-B were not reported to develop a serious side-effect called amyloid-related imaging abnormalities (ARIA).  

The Mini-Mental State Exam (MMSE), used to evaluate cognitive status, showed a slower decline in the low-dose Lomecel-B group versus the placebo group.

The Quality of Life score showed a significantly higher (better) score in the low-dose Lomecel-B group versus the placebo group at six months after the single treatment. 

A high-dose Lomecel-B infusion showed an increase in left hippocampus volume three months after versus placebo.

The hippocampus is a brain region critical for memory formation.

Next Steps: Lomecel-B is being tested in a new larger Phase 2 study, which commenced in December 2021, and has already treated the first patient.

The new trial is designed to evaluate single versus multiple doses of Lomecel-B for mild Alzheimer's Disease.  

Price Action: LGVN shares closed 3.42% higher at $6.95 during after-hours trading on Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareExclusivesGeneralAlzheimer's diseaseAlzheimer’sPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!